CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 15, 2020
Result type: Reports
Project Number: SR0652-000
Product Line: Common Drug Review

Generic Name: ozanimod

Brand Name: TBC

Manufacturer: Celgene Inc.

Indications: Multiple Sclerosis, relapsing - remitting

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS).

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJuly 27, 2020
Call for patient input closedSeptember 16, 2020
Submission receivedAugust 25, 2020
Submission acceptedSeptember 09, 2020
Review initiatedSeptember 14, 2020
Draft CADTH review report(s) provided to sponsor for commentNovember 30, 2020
Deadline for sponsors commentsDecember 09, 2020
CADTH responses on draft review report(s) provided to sponsorJanuary 08, 2021
Expert committee meeting (initial)January 20, 2021
Draft recommendation issuedFebruary 01, 2021
February 03, 2021